These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 31580769)
1. Pembrolizumab and Severe Hypertriglyceridemia Requiring Apheresis: An Immune-Related Adverse Event. Thakker M; Quadri K; Desai A; Illyas W; Kim MY; Desai S; Rager C J Oncol Pract; 2019 Nov; 15(11):613-614. PubMed ID: 31580769 [No Abstract] [Full Text] [Related]
2. Tracheoesophageal Fistula Caused by Successful Response to Pembrolizumab in a Patient With Squamous Cell Lung Cancer. Wang H; Zhang L; Liu W J Thorac Oncol; 2019 Jul; 14(7):e141-e143. PubMed ID: 31235036 [No Abstract] [Full Text] [Related]
3. Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab. Kogure Y; Ishii Y; Oki M J Thorac Oncol; 2019 Mar; 14(3):e55-e57. PubMed ID: 30782385 [No Abstract] [Full Text] [Related]
4. Susac's syndrome as an immune-related adverse event after pembrolizumab: a case report. De Groot M; Compter A; De Langen AJ; Brandsma D J Neurol; 2020 Jan; 267(1):282-284. PubMed ID: 31701330 [No Abstract] [Full Text] [Related]
13. Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer. Blanchard A; Bouchard N Curr Oncol; 2019 Aug; 26(4):e571-e573. PubMed ID: 31548826 [TBL] [Abstract][Full Text] [Related]
14. Prurigo nodularis and pembrolizumab: A therapeutic challenge. Fattore D; Panariello L; Annunziata MC; Fabbrocini G Eur J Cancer; 2019 Mar; 110():8-10. PubMed ID: 30735833 [No Abstract] [Full Text] [Related]
15. In regard to Rosenzweiz et al. IJROBP 2001;50:681-685. Jenkins P Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):878. PubMed ID: 11849815 [No Abstract] [Full Text] [Related]
16. A case of non-small cell lung cancer with danazol-dependent aplastic anemia induced by pembrolizumab. Goda S; Tsuji T; Matsumoto Y; Shiotsu S; Tanaka S; Suga Y; Fujii H; Matsuyama A; Omura A; Yuba T; Takumi C; Hiraoka N Curr Probl Cancer; 2021 Jun; 45(3):100686. PubMed ID: 33293197 [TBL] [Abstract][Full Text] [Related]
17. An unknown reaction to pembrolizumab: giant cell arteritis. Micaily I; Chernoff M Ann Oncol; 2017 Oct; 28(10):2621-2622. PubMed ID: 28633343 [No Abstract] [Full Text] [Related]
18. Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring. Katsume Y; Isawa T; Toi Y; Fukuda R; Kondo Y; Sugawara S; Ootomo T Intern Med; 2018 Nov; 57(21):3157-3162. PubMed ID: 29877257 [TBL] [Abstract][Full Text] [Related]
19. Osteonecrosis of the humeral head in a patient with non-small cell lung cancer receiving bevacizumab. Koczywas M; Cristea MC J Thorac Oncol; 2011 Nov; 6(11):1960-1. PubMed ID: 22005475 [No Abstract] [Full Text] [Related]
20. Durable Response After 2 Doses of Pembrolizumab in a Patient With Non-Small-Cell Lung Cancer With an Isolated Brain Metastasis. Uprety D; Arjyal L; Vallatharasu Y; Bista A; Wittchow RJ; Marinier DE Clin Lung Cancer; 2019 Sep; 20(5):e552-e554. PubMed ID: 31285178 [No Abstract] [Full Text] [Related] [Next] [New Search]